Seeking Alpha recently published the top 50 pharmaceutical companies ranked by their 2010 sales. Number one is of course still Pfizer at $58.4 billion. The number two position changed hands last year though with Novartis ($42.0 B) passing Sanofi ($40.3 B). Merck moved up from number 7 to number 4 with $39.8 B and Roche rounds out the top 5 with $39.1 B.
The top 10 companies account for $352.5 B in sales and 59.4% of total industry revenues. The top 20 companies account for $483.8 B in sales and 81.5% of total industry revenues -- kind of an 80/40 rule for top 50 pharma. All 50 companies in the top 50 had sales topping $2 B. This may yet leave some room for more industry consolidation.
I was interested to see that Teva moved up to number 12 with $16.1 B in sales. Thereby lending some credence to my theory that there will soon become less of a distinction between innovator and generic producers as companies begin competing in both worlds as it were. You can access the entire report below.
Posted by Bruce Lehr Aug 15th 2011.